ACNP 58Th Annual Meeting: Poster Session I
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. -
Clinical Pharmacology of Daridorexant, a Novel Dual Orexin Receptor Antagonist
Clinical pharmacology of daridorexant, a novel dual orexin receptor antagonist Inauguraldissertation zur Erlangung der Würde eines Dr. sc. med. Vorgelegt der Medizinischen Fakultät der Universität Basel Von Clemens Mühlan aus 4055 Basel, Schweiz Basel, 2021 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Medizinischen Fakultät auf Antrag von Prof. Dr. Stephan Krähenbühl Prof. Dr. Matthias Liechti Dr. Alexander Jetter Dr. Jasper Dingemanse Basel, 24. Februar 2021 Dekan Prof. Dr. Primo Leo Schär 2 of 118 TABLE OF CONTENTS LIST OF ABBREVIATIONS AND ACRONYMS ............................................................4 ACKNOWLEDGEMENTS .................................................................................................8 SUMMARY .........................................................................................................................9 1 BACKGROUND AND INTRODUCTION ................................................................15 1.1 Insomnia .......................................................................................................15 1.2 The orexin system as a therapeutic target .....................................................18 1.3 Review of orexin receptor antagonists .........................................................20 1.4 Selective vs dual orexin receptor antagonism ..............................................23 1.5 Orexin receptor antagonists available in clinical practice ............................24 1.6 Orexin receptor -
Hallucinogens: an Update
National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company. -
Photoperiodic Responses on Expression of Clock Genes, Synaptic Plasticity Markers, and Protein Translation Initiators the Impact of Blue-Enriched Light
Photoperiodic Responses on Expression of Clock Genes, Synaptic Plasticity Markers, and Protein Translation Initiators The Impact Of Blue-Enriched Light Master report Jorrit Waslander, s2401878 Behavioral Cognitive Neuroscience research master, N-track University of Groningen, the Netherlands Internship at: Bergen Stress and Sleep Group, University of Bergen, Norway Date: 13-7-2018 Internal supervisor, University of Groningen: P. (Peter) Meerlo External supervisor, University of Bergen: J. (Janne) Grønli Daily supervisor, University of Bergen: A. (Andrea) R. Marti Photoperiodic Responses in the PFC Table of Contents Summary ................................................................................................................................................. 3 Introduction ............................................................................................................................................. 5 Research Objective .............................................................................................................................. 8 Hypotheses .......................................................................................................................................... 8 Methods ................................................................................................................................................ 10 Experimental procedure .................................................................................................................... 10 Ethics ............................................................................................................................................ -
Orexins, Sleep, and Blood Pressure
Current Hypertension Reports (2018) 20: 79 https://doi.org/10.1007/s11906-018-0879-6 SLEEP AND HYPERTENSION (SJ THOMAS, SECTION EDITOR) Orexins, Sleep, and Blood Pressure Mariusz Sieminski1 & Jacek Szypenbejl1 & Eemil Partinen2,3 Published online: 10 July 2018 # The Author(s) 2018 Abstract Purpose of Review The aim of this review was to summarize collected data on the role of orexin and orexin neurons in the control of sleep and blood pressure. Recent Findings Although orexins (hypocretins) have been known for only 20 years, an impressive amount of data is now available regarding their physiological role. Hypothalamic orexin neurons are responsible for the control of food intake and energy expenditure, motivation, circadian rhythm of sleep and wake, memory, cognitive functions, and the cardiovascular system. Multiple studies show that orexinergic stimulation results in increased blood pressure and heart rate and that this effect may be efficiently attenuated by orexinergic antagonism. Increased activity of orexinergic neurons is also observed in animal models of hypertension. Summary Pharmacological intervention in the orexinergic system is now one of the therapeutic possibilities in insomnia. Although the role of orexin in the control of blood pressure is well described, we are still lacking clinical evidence that this is a possibility for a new approach in the treatment of cardiovascular diseases. Keywords Orexin . Hypocretin . Blood pressure . Sleep . Narcolepsy . Autonomic nervous system Introduction cardiovascular system. With such a variety of functions, orexins appear to be a promising target for therapeutic in- We are celebrating the twentieth anniversary of the discov- terventions aimed at solving the most pivotal health prob- ery of hypocretins/orexins. -
Anatomical and Behavioral Investigation of C1ql3 in the Mouse Suprachiasmatic Nucleus David C
University of Connecticut OpenCommons@UConn UCHC Articles - Research University of Connecticut Health Center Research 6-2017 Anatomical and Behavioral Investigation of C1ql3 in the Mouse Suprachiasmatic Nucleus David C. Martinelli University of Connecticut School of Medicine and Dentistry Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons Recommended Citation Martinelli, David C., "Anatomical and Behavioral Investigation of C1ql3 in the Mouse Suprachiasmatic Nucleus" (2017). UCHC Articles - Research. 311. https://opencommons.uconn.edu/uchcres_articles/311 HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Biol Rhythms Manuscript Author . Author Manuscript Author manuscript; available in PMC 2017 November 01. Published in final edited form as: J Biol Rhythms. 2017 June ; 32(3): 222–236. doi:10.1177/0748730417704766. Anatomical and Behavioral Investigation of C1ql3 in the Mouse Suprachiasmatic Nucleus Kylie S. Chew*,†, Diego C. Fernandez*,1, Samer Hattar*,‡,1, Thomas C. Südhof§,‖, and David C. Martinelli§,¶,2 *Department of Biology, The Johns Hopkins University, Baltimore, Maryland †Department of Biology, Stanford University School of Medicine, Stanford, California ‡The Solomon Snyder- Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland §Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California ‖Howard Hughes -
The Photoreceptors and Neural Circuits Driving the Pupillary Light Reflex
THE PHOTORECEPTORS AND NEURAL CIRCUITS DRIVING THE PUPILLARY LIGHT REFLEX by Alan C. Rupp A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland January 28, 2016 This work is protected by a Creative Commons license: Attribution-NonCommercial CC BY-NC Abstract The visual system utilizes environmental light information to guide animal behavior. Regulation of the light entering the eye by the pupillary light reflex (PLR) is critical for normal vision, though its precise mechanisms are unclear. The PLR can be driven by two mechanisms: (1) an intrinsic photosensitivity of the iris muscle itself, and (2) a neural circuit originating with light detection in the retina and a multisynaptic neural circuit that activates the iris muscle. Even within the retina, multiple photoreceptive mechanisms— rods, cone, or melanopsin phototransduction—can contribute to the PLR, with uncertain relative importance. In this thesis, I provide evidence that the retina almost exclusively drives the mouse PLR using bilaterally asymmetric brain circuitry, with minimal role for the iris intrinsic photosensitivity. Intrinsically photosensitive retinal ganglion cells (ipRGCs) relay all rod, cone, and melanopsin light detection from the retina to brain for the PLR. I show that ipRGCs predominantly relay synaptic input originating from rod photoreceptors, with minimal input from cones or their endogenous melanopsin phototransduction. Finally, I provide evidence that rod signals reach ipRGCs using a non- conventional retinal circuit, potentially through direct synaptic connections between rod bipolar cells and ipRGCs. The results presented in this thesis identify the initial steps of the PLR and provide insight into the precise mechanisms of visual function. -
Royalty Pharma Minerva Press Release January 19 2021
ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN SELTOREXANT FROM MINERVA NEUROSCIENCES NEW YORK, NY and WALTHAM, MA, January 19, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional milestone payments. The additional payments to Minerva will be contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson. “We are very pleased to have entered into this agreement with Royalty Pharma, the leader in acquiring pharmaceutical royalties across the life sciences industry,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “The proceeds will be used to fund continued development of roluperidone, the Company’s proprietary lead compound, which is in Phase 3 development to treat negative symptoms in schizophrenia.” “We are delighted to partner with Minerva,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “Based on seltorexant’s differentiated mechanism of action and robust clinical evidence to date, we are excited by the therapy’s emerging profile and the opportunity it may bring to address a significant unmet need for the millions of patients with major depressive disorder with insomnia symptoms.” Minerva Neurosciences is entitled to a mid-single digit royalty on worldwide net sales of seltorexant. Cooley acted as legal advisors to Minerva Neurosciences on the transaction. -
UC San Diego Electronic Theses and Dissertations
UC San Diego UC San Diego Electronic Theses and Dissertations Title Ultrastructure of Melanopsin-Expressing Retinal Ganglion Cell Circuitry in the Retina and Brain Regions that Mediate Light-Driven Behavior Permalink https://escholarship.org/uc/item/8kd9v9xp Author Liu, Yu Hsin Publication Date 2017 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, SAN DIEGO Ultrastructure of Melanopsin-Expressing Retinal Ganglion Cell Circuitry in the Retina and Brain Regions that Mediate Light-Driven Behavior A dissertation submitted in partial satisfaction of the Requirements for the degree Doctor of Philosophy in Neurosciences by Yu Hsin Liu Committee in charge: Professor Satchidananda Panda, Chair Professor Mark Ellisman, Co-Chair Professor Nicola Allen Professor Brenda Bloodgood Professor Ed Callaway Professor David Welsh 2017 Copyright Yu Hsin Liu, 2017 All rights reserved. This Dissertation of Yu Hsin Liu is approved, and it is acceptable in quality and form for publication on microfilm and electronically: _________________________________________ _________________________________________ _________________________________________ _________________________________________ _________________________________________ Co-Chair _________________________________________ Chair University of California, San Diego 2017 iii TABLE OF CONTENTS Signature Page ..................................................................................................... iii Table -
Distinct Iprgc Subpopulations Mediate Light's Acute and Circadian
RESEARCH ARTICLE Distinct ipRGC subpopulations mediate light’s acute and circadian effects on body temperature and sleep Alan C Rupp1, Michelle Ren2, Cara M Altimus1, Diego C Fernandez1†, Melissa Richardson1, Fred Turek2, Samer Hattar1,3†, Tiffany M Schmidt2* 1Department of Biology, Johns Hopkins University, Baltimore, United States; 2Department of Neurobiology, Northwestern University, Evanston, United States; 3Department of Neuroscience, Johns Hopkins University, Baltimore, United States Abstract The light environment greatly impacts human alertness, mood, and cognition by both acute regulation of physiology and indirect alignment of circadian rhythms. These processes require the melanopsin-expressing intrinsically photosensitive retinal ganglion cells (ipRGCs), but the relevant downstream brain areas involved remain elusive. ipRGCs project widely in the brain, including to the central circadian pacemaker, the suprachiasmatic nucleus (SCN). Here we show that body temperature and sleep responses to acute light exposure are absent after genetic ablation of all ipRGCs except a subpopulation that projects to the SCN. Furthermore, by chemogenetic activation of the ipRGCs that avoid the SCN, we show that these cells are sufficient for acute changes in body temperature. Our results challenge the idea that the SCN is a major relay for the acute effects of light on non-image forming behaviors and identify the sensory cells that initiate light’s profound effects on body temperature and sleep. *For correspondence: DOI: https://doi.org/10.7554/eLife.44358.001 [email protected] Present address: †National Institute of Mental Health, Introduction Bethesda, United States Many essential functions are influenced by light both indirectly through alignment of circadian Competing interests: The rhythms (photoentrainment) and acutely by a direct mechanism (sometimes referred to as ‘masking’) authors declare that no (Mrosovsky et al., 1999; Altimus et al., 2008; Lupi et al., 2008; Tsai et al., 2009; LeGates et al., competing interests exist. -
BMC Neuroscience Biomed Central
BMC Neuroscience BioMed Central Research article Open Access Regulation of prokineticin 2 expression by light and the circadian clock Michelle Y Cheng1, Eric L Bittman2, Samer Hattar3 and Qun-Yong Zhou*1 Address: 1Department of Pharmacology, University of California, Irvine, CA, USA, 2Department of Biology, University of Massachusetts, Amherst, MA, USA and 3Departments of Biology and Neuroscience, Johns Hopkins University, Baltimore, MD, USA Email: Michelle Y Cheng - [email protected]; Eric L Bittman - [email protected]; Samer Hattar - [email protected]; Qun- Yong Zhou* - [email protected] * Corresponding author Published: 11 March 2005 Received: 17 November 2004 Accepted: 11 March 2005 BMC Neuroscience 2005, 6:17 doi:10.1186/1471-2202-6-17 This article is available from: http://www.biomedcentral.com/1471-2202/6/17 © 2005 Cheng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: The suprachiasmatic nucleus (SCN) contains the master circadian clock that regulates daily rhythms of many physiological and behavioural processes in mammals. Previously we have shown that prokineticin 2 (PK2) is a clock-controlled gene that may function as a critical SCN output molecule responsible for circadian locomotor rhythms. As light is the principal zeitgeber that entrains the circadian oscillator, and PK2 expression is responsive to nocturnal light pulses, we further investigated the effects of light on the molecular rhythm of PK2 in the SCN. -
Acute Dose-Dependent Effects of Lysergic Acid Diethylamide in a Double-Blind Placebo-Controlled Study in Healthy Subjects
www.nature.com/npp ARTICLE OPEN Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects Friederike Holze 1,2, Patrick Vizeli 1,2, Laura Ley1,2, Felix Müller3, Patrick Dolder1,2, Melanie Stocker1,2, Urs Duthaler1,2, Nimmy Varghese3,4, Anne Eckert 3,4, Stefan Borgwardt3 and Matthias E. Liechti 1,2 Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD. We used a double-blind, randomized, placebo-controlled, crossover design in 16 healthy subjects (eight women, eight men) who underwent six 25 h sessions and received placebo, LSD (25, 50, 100, and 200 µg), and 200 µg LSD 1 h after administration of the serotonin 5- hydroxytryptamine-2A (5-HT2A) receptor antagonist ketanserin (40 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales that evaluated subjective effects, autonomic effects, adverse effects, plasma brain-derived neurotrophic factor levels, and pharmacokinetics up to 24 h. The pharmacokinetic-subjective response relationship was evaluated. LSD showed dose-proportional pharmacokinetics and first-order elimination and dose-dependently induced subjective responses starting at the 25 µg dose. A ceiling effect was observed for good drug effects at 100 µg. The 200 µg dose of LSD induced greater ego dissolution than the 100 µg dose and induced significant anxiety. The average duration of subjective effects increased from 6.7 to 11 h with increasing doses of 25–200 µg.